Brown Advisory Inc. Acquires 112,170 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Brown Advisory Inc. lifted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 25.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 556,209 shares of the company's stock after purchasing an additional 112,170 shares during the quarter. Brown Advisory Inc. owned about 0.45% of Vaxcyte worth $45,531,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Whipplewood Advisors LLC acquired a new stake in Vaxcyte in the 4th quarter valued at approximately $28,000. Smartleaf Asset Management LLC raised its holdings in Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after acquiring an additional 260 shares in the last quarter. National Bank of Canada FI bought a new position in Vaxcyte in the fourth quarter valued at approximately $41,000. Blue Trust Inc. increased its position in shares of Vaxcyte by 100.0% during the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after purchasing an additional 371 shares during the last quarter. Finally, Assetmark Inc. raised its stake in shares of Vaxcyte by 77,500.0% during the 4th quarter. Assetmark Inc. now owns 776 shares of the company's stock worth $64,000 after purchasing an additional 775 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Stock Down 0.9 %

Shares of PCVX traded down $0.29 during midday trading on Friday, reaching $31.16. 2,030,375 shares of the stock were exchanged, compared to its average volume of 1,306,324. The stock's 50 day simple moving average is $46.66 and its 200 day simple moving average is $74.72. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $121.06. The company has a market cap of $4.02 billion, a P/E ratio of -6.77 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same quarter in the previous year, the company posted ($0.85) earnings per share. As a group, analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. The Goldman Sachs Group dropped their target price on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Guggenheim reiterated a "buy" rating and issued a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, March 12th. Needham & Company LLC restated a "buy" rating and issued a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th. Finally, Bank of America reduced their target price on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Vaxcyte has a consensus rating of "Buy" and a consensus price target of $136.50.

Insider Transactions at Vaxcyte

In related news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total transaction of $586,160.00. Following the transaction, the chief operating officer now owns 154,931 shares of the company's stock, valued at $11,351,794.37. The trade was a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.